Arbor Biotechnologies (Series C)
Funding Details
- Awarder
- Inbox
- Date Award
- March 18, 2025
- Vertical
- Genetic Medicine
- Funding URL
- View Funding Page
- Funding Amount:
- $74,000,000
Company Info
- Traction
- The company is advancing its lead program into clinical testing with a Phase 1/2 trial planned to enroll about two dozen volunteers.
- Company Description
- Arbor Biotechnologies is developing gene editing therapies for rare diseases, specifically targeting primary hyperoxaluria type 1 with its lead program ABO-101, which aims to provide a one-time treatment solution.
- Market
- Rare Diseases
- Location
- USA
- Coinvestors
- Arch Venture Partners, TCGX